According to Benzinga, in a research note distributed to investors on Monday, Raymond James increased their price objective for Simulations Plus (NASDAQ: SLP) from $54.00 to $70.00. The company reported this news. There is currently an “outperform” rating on the company’s shares of the information technology provider. From the most recent price at which the stock was traded, the share’s price has the potential to increase by 14.34%, according to the price objective that Raymond James provided.
Simulations Plus, which boasts positive prospects for growth, is a company whose stock investors should keep an eye on in the healthcare sector. In recent days, several additional stock research analysts have made public their findings about the company that was the subject of their investigation. The results of a study made available to the public on Friday, July 22, showed that TheStreet upgraded Simulations Plus from a rating of “c+” to a rating of “b-.”
The research report that Craig Hallum published on July 7 recommended a “buy” rating for the company and increased the target price for Simulations Plus from $55.00 to $60.00 and increased the target price from $55.00 to $60.00. Two analysts have suggested that investors keep their current position in the company’s shares, while two other analysts have suggested that investors buy stock in the company. Two experts have suggested that investors keep their current position in the company’s shares. According to the information provided by Bloomberg, the stock is currently rated as having an average rating of “Moderate Buy,” and it has an established price target of $65.00.
The first day of trading for SLP shares was Monday, and the opening price was $61.22. The all-time low for Simulations Plus was $35.18, while the all-time high for the company was $67.59 in the most recent year. The moving averages for the previous 50 days at the company are $58.36, and the moving averages for the previous 200 days are $49.82. The current P/E ratio for the company is 107.41, and it has a beta value of 0.42. The market value for the company is currently $1.24 billion.
On July 6, the most recent earnings report for Simulations Plus, which is publicly traded and can be found under the symbol NASDAQ: SLP, was made available to the public. Simulations Plus reported a return on equity of 6.91% for the most recent quarter, and its net margin was 22.74%. It led to earnings per share of $0.20, which was $0.03 more than the average prediction of $0.17. In other words, the earnings per share exceeded expectations by $0.03. The company reported total revenue of $14.96 million for the quarter, which was significantly higher than the consensus forecast of $14.33 million.
During the same period the year before, the company posted earnings per share of $0.18. The company’s quarterly revenue increased by 17.1% when measured against the results achieved during the same quarter in the preceding year. Equity research analysts anticipate that Simulations Plus will generate $0.64 in profit per share this year. On Wednesday, July 27, other significant events took place, including the sale of 20,000 shares of the company’s stock by Director Walter S. Woltz.
The sale of the shares resulted in total revenue of $1,223,800.00, with the average price at which each share could be purchased being $61.19. After the completion of the transaction, the director now owns 4,117,634 shares of the company. The total value of these shares is $251,958,024.46. The transaction was disclosed in a filing with the SEC, which can be viewed entirely by following this link. In additional relevant information regarding this topic, On Wednesday, July 27, Walter S. Woltosz, who serves as director of Simulations Plus, sold 20,000 shares of the company’s stock.
The sale of the shares resulted in total revenue of $1,223,800.00, with the average price at which each share could be purchased being $61.19. Following the conclusion of the transaction, the director now owns 4,117,634 shares of the company. The total value of these shares is approximately $251,958,024.46. On the website of the Securities and Exchange Commission (SEC), there is currently a document that has been filed with them that details the transaction in greater detail. On June 28, Walter S. Woltosz, both a director and shareholder of Simulations Plus, sold 17,461 shares of the company’s stock.
After selling the shares at an average price of $48, the director now owns 4,140,173 shares of the company’s stock, which has an approximate value of $198,728,304. The shares were sold for $838,128.00, an average price of $80.00 per share. Disclosures that are related to the sale might be found in this section of the website. The company’s management and employees collectively own 23.08% of the company’s shares. Recent events have resulted in changes being made to the total amount of SLP held by hedge funds and other institutional investors.
The final three months of 2018 saw Cambridge Investment Research Advisors Inc. invest an additional $235,000 in Simulations Plus stock by purchasing additional company shares. In the final quarter of 2018, Victory Capital Management Inc. increased the total number of shares of Simulations Plus owned by 16.6%. The technology company’s stock was increased by 1,056 shares during the most recent fiscal quarter, bringing the total number of shares owned by Victory Capital Management Inc. to 7,411. The total value of these shares comes to $351,000. The final three months of 2018 saw Baird Financial Group, Inc. make a new investment in Simulations Plus valued at close to $250,000 at the time of the transaction.
During the fourth quarter, Dimensional Fund Advisors LP saw a 96.6% increase in its investment value in Simulations Plus. The technology company now has a total of 80,316 shares of the stock that Dimensional Fund Advisors LP holds after the acquisition of an additional 39,472 shares during the most recent quarter. There is a value of $3,799,000 attached to these shares. The most recent transaction was finalized during the last three months when Buckingham Strategic Wealth LLC purchased a new stake in Simulations Plus for close to $215,000. Most of the company’s stock is owned by institutional investors and hedge funds, accounting for 72.51 percent of the total.
To model, simulate, and predict the chemical properties of potential drugs, the company Simulations Plus, Inc., which specializes in drug research and development software, uses both artificial intelligence and machine learning. It allows the company to model, simulate, and predict the chemical properties of potential medications. The business is structured with four departments, which are named as follows: Simulations Plus, Cognigen, DILIsym, and Lixoft.
